Tesamorelin
From PeptideSciences101, the open peptide reference. · Last updated: October 21, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
FDA-approved for HIV lipodystrophy. Reduces abdominal fat.
Reported benefits
Visceral fat reduction, improved body composition, GH release
Protocols & dosing
Typical dosage: 2 mg (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Tesamorelin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Joint pain, peripheral edema
References
No external sources have been catalogued for this article yet.
Related peptides
- ACE-031 — Myostatin inhibitor
- CJC-1295 — Growth hormone, muscle mass, fat loss
- Epithalon + Follistatin Stack — Anti-aging performance combo
- GHRP-4 — Fourth generation GHRP
- Hexarelin — Potent GH releaser
- HGH Fragment 176-191 — Fat loss without GH effects
Categories: Performance & Growth